Carbonyl Reductase Expression and Its Clinical Significance in Non–Small-Cell Lung Cancer
暂无分享,去创建一个
H. Wada | F. Tanaka | K. Takenaka | H. Oyanagi | E. Ogawa
[1] Thomas J. Smith,et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] J. Castelao,et al. Lung cancer and cyclooxygenase-2. , 2003, The Annals of thoracic surgery.
[3] M. Dohadwala,et al. Autocrine/Paracrine Prostaglandin E2 Production by Non-small Cell Lung Cancer Cells Regulates Matrix Metalloproteinase-2 and CD44 in Cyclooxygenase-2-dependent Invasion* , 2002, The Journal of Biological Chemistry.
[4] M. Brundage,et al. Prognostic factors in non-small cell lung cancer: a decade of progress. , 2002, Chest.
[5] P. Hahnfeldt,et al. Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. , 2002, Journal of the National Cancer Institute.
[6] A. Tarnawski,et al. Prostaglandin E2 transactivates EGF receptor: A novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy , 2002, Nature Medicine.
[7] H. Wada,et al. Evaluation of angiogenesis in non-small cell lung cancer: comparison between anti-CD34 antibody and anti-CD105 antibody. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[8] S. Tsuchida,et al. Carbonyl reductase as a significant predictor of survival and lymph node metastasis in epithelial ovarian cancer , 2001, British Journal of Cancer.
[9] T. Moody,et al. Prostaglandin E2 and vasoactive intestinal peptide increase vascular endothelial cell growth factor mRNAs in lung cancer cells. , 2001, Lung cancer.
[10] H. Wada,et al. Surgery for non-small cell lung cancer: postoperative survival based on the revised tumor-node-metastasis classification and its time trend. , 2000, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.
[11] S. Tsuchida,et al. Carbonyl reductase: a novel metastasis-modulating function. , 2000, Cancer research.
[12] S. Kumar,et al. Breast carcinoma: vascular density determined using CD105 antibody correlates with tumor prognosis. , 1999, Cancer research.
[13] Li Zhu,et al. Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production. , 1998, Cancer research.
[14] J. Morrow,et al. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. , 1998, Cancer research.
[15] M. Kelner,et al. Heterologous expression of carbonyl reductase: demonstration of prostaglandin 9-ketoreductase activity and paraquat resistance. , 1997, Life sciences.
[16] C. Mountain,et al. Revisions in the International System for Staging Lung Cancer. , 1997, Chest.
[17] C. Bernabéu,et al. EDITORIAL. CD105 AND ANGIOGENESIS , 1996 .
[18] Yung‐Chie Lee,et al. Tumor angiogenesis correlates with histologic type and metastasis in non-small-cell lung cancer. , 1995, American journal of respiratory and critical care medicine.
[19] J. Doroshow,et al. Protection against daunorubicin cytotoxicity by expression of a cloned human carbonyl reductase cDNA in K562 leukemia cells. , 1995, Cancer research.
[20] E. Maser,et al. Xenobiotic carbonyl reduction and physiological steroid oxidoreduction. The pluripotency of several hydroxysteroid dehydrogenases. , 1995, Biochemical pharmacology.
[21] S. Rodan,et al. Induction of vascular endothelial growth factor expression by prostaglandin E2 and E1 in osteoblasts. , 1994, The Journal of clinical investigation.
[22] B. Wermuth,et al. Immunohistochemical localization of carbonyl reductase in human tissues. , 1992, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[23] C. Angeletti,et al. Relation of neovascularisation to metastasis of non-small-cell lung cancer , 1992, The Lancet.
[24] A. Schieber,et al. Purification and properties of prostaglandin 9-ketoreductase from pig and human kidney. Identity with human carbonyl reductase. , 1992, European journal of biochemistry.
[25] A. Fulton,et al. Role of the prostaglandin E2 receptor in mammary tumor metastasis. , 1991, Cancer research.
[26] F. Oesch,et al. Carbonyl reductase provides the enzymatic basis of quinone detoxication in man. , 1986, Biochemical pharmacology.
[27] G. Forrest,et al. Carbonyl reductase. , 2000, Chemico-biological interactions.
[28] M. Hayakari,et al. Decreased expression of the peroxisomal bifunctional enzyme and carbonyl reductase in human hepatocellular carcinomas , 1999, Journal of Cancer Research and Clinical Oncology.